BiotechTube

celecoxib + ibuprofen + placebo

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ischemic Heart Disease

Conditions

Ischemic Heart Disease, Osteoarthritis

Trial Timeline

Apr 1, 2003 → Apr 1, 2005

NCT ID
NCT00565500

About celecoxib + ibuprofen + placebo

celecoxib + ibuprofen + placebo is a approved stage product being developed by Pfizer for Ischemic Heart Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00565500. Target conditions include Ischemic Heart Disease, Osteoarthritis.

What happened to similar drugs?

9 of 13 similar drugs in Ischemic Heart Disease were approved

Approved (9) Terminated (3) Active (4)
✅RegadenosonAstellas PharmaApproved
✅StatinShionogiApproved
✅RepathaAmgenApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅Eplerenone + Placebo or sugar pillPfizerApproved
✅Enoxaparin sodiumSanofiApproved
✅Huatuo Zaizao PillsGuangzhou Baiyunshan Pharmaceutical HoldingsApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00565500ApprovedCompleted

Competing Products

20 competing products in Ischemic Heart Disease

See all competitors
ProductCompanyStageHype Score
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
RegadenosonAstellas PharmaPhase 1
29
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
RegadenosonAstellas PharmaApproved
43
ASP2246Astellas PharmaPhase 1/2
39
Gadolinium + AdenosineAstellas PharmaPhase 2/3
38
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
fospropofol + propofolEisaiPhase 2
35
PDE5 InhibitorsEli LillyPre-clinical
26
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
42
Elezanumab + PlaceboAbbViePhase 2
35
Balovaptan + PlaceboRochePhase 2
27
RepathaAmgenApproved
35